Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop
Lawrence J. Lesko(University of Florida), Alexandra S. Worobec(Loyola University Medical Center), Frank D. Sistare(United States Military Academy), Shiew‐Mei Huang(United States Food and Drug Administration), Mark L Watson(United States Military Academy), Jerry M. Collins(National Institutes of Health), Ronald A. Salerno, Peter Shaw(Wenzhou Medical University), C. Brazell(GlaxoSmithKline (Germany)), Joanne Killinger, Joseph Hackett(Center for Devices and Radiological Health), Baltazar Gomez‐Mancilla(Novartis (Switzerland)), Stephen G. Ryan(New York University), Virginia D. Schmith(Research Triangle Park Foundation), Donald C. Anderson(Children's Hospital of Philadelphia), Brian B. Spear(Abbott Fund), Elizabeth Mansfield(Center for Devices and Radiological Health), John K. Leighton, Robert J. Meyer(University of Pennsylvania), Andrew J. Dorner, David M. Essayan(Center for Biologics Evaluation and Research), Timothy S. Anderson(University of California, San Francisco), Susan Ide(Novartis (United States))
Cited by 123
Related Papers
Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23
|Science|1996|784
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
MAIT cells are activated during human viral infections
|Nature Communications|2016|526